ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Malignancy"

  • 2021 American Transplant Congress

    Long Term Survival After Liver Transplantation for Advanced, Unresectable Intrahepatic Cholangiocarcinoma

    R. R. McMillan1, S. Kodali1, M. Javle2, A. Saharia1, C. M. Mobley1, M. J. Hobeika1, A. Shetty1, D. W. Victor1, R. McFadden1, M. Abdelrahim1, K. Heyne1, A. O. Gaber1, R. M. Ghobrial1

    1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

    *Purpose: Intrahepatic cholangiocarcinoma (ICCA) has traditionally been considered a contraindication to liver transplantation (LT). We previously reported a case series of six patients with large,…
  • 2021 American Transplant Congress

    Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions

    W. Piao, R. Oakes, C. Paluskievicz, J. Christopher, J. Bromberg

    U Maryland, Baltimore, MD

    *Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…
  • 2021 American Transplant Congress

    Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term

    T. Schachtner, J. Fuhrmann, T. Mueller

    Nephrology, University Hospital Zurich, Zurich, Switzerland

    *Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
  • 2021 American Transplant Congress

    Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma

    S. Kumar1, S. Lin2, J. D. Schold2

    1Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

    *Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…
  • 2021 American Transplant Congress

    Excellent Pathological Response with Gemcitabine-based Protocol in Patient with Hilar Cholangiocarcinoma

    A. Saharia1, R. McMillan1, S. Kodali1, M. Javley2, C. M. Mobley1, M. J. Hobeika1, A. Shetty1, D. W. Victor1, R. McFadden1, M. Abdelrahim1, K. Heyne1, A. O. Gaber1, R. M. Ghobrial1

    1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

    *Purpose: The standard treatment for hilar cholangiocarcinoma is using 5FU along with brachytherapy and external beam radiation. The downside of this regimen is the uncertain…
  • 2021 American Transplant Congress

    Outcomes of Surgical Resection versus Liver Transplantation in Hilar Cholangiocarcinoma

    M. K. White1, F. Aucejo2, A. Moro2, K. Sasaki2, K. Stephans3, B. Estfan4, C. Quintini2, B. Eghtesad2, K. Hashimoto2, F. Masato2, C. Miller2, K. Menon5

    1Cleveland Clinic, Cleveland, OH, 2General Surgery, Cleveland Clinic, Cleveland, OH, 3Radiation Oncology, Cleveland Clinic, Cleveland, OH, 4Oncology, Cleveland Clinic, Cleveland, OH, 5Gastroenterology & Hepatology, Cleveland Clinic, Cleveland, OH

    *Purpose: To compare the outcomes of patients with hilar cholangiocarcinoma (hCCA) who underwent either surgical resection or liver transplantion (LT).*Methods: All hCCA patients who underwent…
  • 2021 American Transplant Congress

    Incidentally Detected Malignancies in Lung Explants: Single Center Case Series

    D. Razia, A. Arjuna, L. Schaheen, J. Huang, M. Smith, R. Bremner, R. Walia

    Thoracic Surgery and Lung Transplantation, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

    *Purpose: Thoracic malignancies are difficult to prospectively diagnose in patients with end-stage lung disease due to complex radiologic features. We present a series of lung…
  • 2021 American Transplant Congress

    Cancer-Specific Mortality in Solid Organ Transplant Recipients with a Prior Cancer Diagnosis

    E. Engels1, G. Haber1, A. Hart2, C. Lynch3, J. Li4, K. Pawlish4, B. Qiao5, K. Yu1, R. Pfeiffer1

    1Natl Cancer Inst, Bethesda, MD, 2Univ of Minnesota, Minneapolis, MN, 3Univ of Iowa, Iowa City, IA, 4New Jersey Dept of Health, Trenton, NJ, 5New York State Dept of Health, Albany, NY

    *Purpose: A history of cancer is increasingly common among solid organ transplant candidates, and transplant-associated immunosuppression may increase recurrence risk. We assessed whether transplantation was…
  • 2021 American Transplant Congress

    Review of Outcomes After Diagnosis of Malignancy in Kidney Transplant Patients: Unos Database

    H. Patel1, N. Agrawal1, R. Gupta1, P. Geetha2, A. Abdul Razzack3, F. Cardarelli1

    1Transplant Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, 2Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, 3Medicine, Dr. NTR University of Health Sciences, Vijaywada, India

    *Purpose: Malignancy is the third major cause of death among transplant recipients. Among the transplant recipients, Patient and kidney transplant outcomes after the diagnosis of…
  • 2020 American Transplant Congress

    Donor Derived Transmissions 2018: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)

    M. Michaels1, B. Plucinski2, E. Ward2, L. Strasfeld1, M. Malinis1, C. Ho1, L. Danziger-Isakov1, J. Bucio1, G. Berry1, M. Rana1, C. Marboe1, S. Aslam1, R. Razonable1, S. Pouch1, G. F. Marklin1, J. Levitsky1, D. Levine1, A. Agarwal1, R. LaHoz1

    1OPTN DTAC, Richmond, VA, 2UNOS, Richmond, VA

    *Purpose: The OPTN DTAC, a multidisciplinary group, evaluates potential donor derived transmission events (PDDTE), mostly infections (I) & malignancies (M), to assess the likelihood of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 20
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences